Zenlabs Ethica Share Price
Small Cap | Pharmaceuticals and health care | BSE: 530697
₹31.39 
-1.30 (-3.98 %)
Last Updated: 30 Apr 2025 04:01 PM
Technicals
BEARISH
BEARISHOverview
Open (₹) 31.06
High (₹) 33.40
Low (₹) 31.06
Prev. Close (₹) 32.69
Volume 1,773
VWAP (₹) 32.20
ROCE (%) 10.69
Industry P/E 46.55
TTM P/E 61.55
P/B Ratio 2.02
Market Cap (₹) Cr.20.43
Dividend Yield (%)--
EPS (₹) 0.65
ROE4.18%
Sales Growth (%) -12.44
Profit Growth (%)-13.92
Day Range
33.4033.40
52 Week Range
27.3352.40
Historical Returns
Returns (6M)
-25.05 %
Returns (1Y)
-33.21 %
Returns (3Y)
-5.74 %
Returns (5Y)
4.63 %
Returns (6M)
-25.05 %
Returns (1Y)
-33.21 %
Returns (3Y)
-5.74 %
Returns (5Y)
4.63 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Strong short-term momentum: Price above short-term moving averages (EMA_10)
Technicals
Technical Rating
Trend BEARISH
BEARISHMoving Averages
Technical Indicators
Bearish
Bearish
RSI 55.99
MFI 26.92
ATR 3.18
Commodity Channel Index 14.81
ROC125 -23.94
ROC21 3.99
Williams %R -48.43
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 32.76 | 34.25 | 35.10 | 31.91 | 30.42 | 29.57 | 28.08 |
| Week Ago | 30.66 | 31.75 | 32.50 | 29.91 | 28.82 | 28.07 | 26.98 |
| Month Ago | 33.15 | 35.20 | 36.50 | 31.85 | 29.80 | 28.50 | 26.45 |
EMA & SMA
31.39
Current Price
Bullish Moving Averages
7
Bearish Moving Averages
13
5 Day 30.73
9 Day 31.62
10 Day 31.36
12 Day 31.51
14 Day 31.34
20 Day 31.58
26 Day 31.66
50 Day 32.73
100 Day 35.89
200 Day 38.53
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| USHA JAWAHARLAL KALRO | bulk | Sell | 21st Mar, 2025 | ₹31.86 | 6,500 | BSE |
| HITESH BASANT SUNDESHA | bulk | Sell | 21st Mar, 2025 | ₹30.99 | 36,972 | BSE |
| USHA JAWAHARLAL KALRO | bulk | Buy | 21st Mar, 2025 | ₹30.99 | 43,854 | BSE |
| HITESH BASANT SUNDESHA | bulk | Buy | 20th Mar, 2025 | ₹31.03 | 36,972 | BSE |
| HARISH KUMAR | bulk | Sell | 10th Oct, 2024 | ₹40.96 | 46,100 | BSE |
| RAKESH KUMAR ARORA | bulk | Buy | 24th Feb, 2023 | ₹61.28 | 32,633 | BSE |
| PREET REMEDIES PRIVATE LIMITE | bulk | Sell | 9th Nov, 2022 | ₹76.45 | 45,473 | BSE |
| ABHIK NARENDRABHAI PATEL | bulk | Buy | 9th Nov, 2022 | ₹76.44 | 53,000 | BSE |
| PREET REMEDIES PRIVATE LIMITE | bulk | Sell | 30th Aug, 2022 | ₹56.02 | 40,000 | BSE |
| ABHIK NARENDRABHAI PATEL | bulk | Sell | 30th Aug, 2022 | ₹55.92 | 10,000 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 23rd Mar, 2024 | PREET REMEDIES LIMITED | Disposal | ₹52.22 | 4,00,000 | BSE |
| 10th Nov, 2022 | PREET REMEDIES LIMITED | Disposal | ₹75.91 | 45,001 | BSE |
| 9th Sept, 2022 | PREET REMEDIES LIMITED | Disposal | ₹62.85 | 30,000 | BSE |
| 2nd Sept, 2022 | PREET REMEDIES LIMITED | Disposal | ₹55.40 | 57,253 | BSE |
| 25th Aug, 2022 | PREET REMEDIES LIMITED | Disposal | ₹46.50 | 56,518 | BSE |
| 19th Aug, 2022 | PREET REMEDIES LIMITED | Disposal | ₹45.50 | 16,380 | BSE |
| 19th Aug, 2022 | PREET REMEDIES LIMITED | Acquisition | ₹45.40 | 349 | BSE |
| 19th Aug, 2022 | PREET REMEDIES LIMITED | Disposal | ₹44.51 | 21,029 | BSE |
| 27th Jun, 2022 | PREET REMEDIES LIMITED | Disposal | ₹48.20 | 50,000 | BSE |
| 25th Jun, 2022 | PREET REMEDIES LIMITED | Disposal | ₹41.47 | 75,000 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 20th Jul, 2022 | Rs.0.2500 per share(2.5%)Interim Dividend | 29th Jul, 2022 | 1st Aug, 2022 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 10th Apr, 2025 | BSE India | Compliance Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2025. |
| 5th Apr, 2025 | BSE India | <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Zenlabs Ethica Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L74900CH1993PLC033112</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2024-2025</td> </tr> <tr><td colspan=''3''>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2024-25, 2025-26</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d), which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)(f) = (b) - (c) - (e) If the calculated value is zero or negative, write 'nil'*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=''2''><b>Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2023-24, 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block, if applicable Fine = 0.2% of (d) - (e)#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Manju Bala</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Adarsh Sharma</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 05/04/2025<br/><br/></div> |
| 5th Apr, 2025 | BSE India | <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Zenlabs Ethica Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L74900CH1993PLC033112</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=''float:left;''> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No</div> <br/><br/><br/> <div style=''float:left;''> Name of the Company Secretary: Manju Bala <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: secretarial@zenlabsethica.com</div> <div ''style=float:left;margin-left:50px;''> Name of the Chief Financial Officer: Adarsh Sharma <br/> Designation: Chief Financial Officer <br/> EmailId: zenlabsethicaltd2019@gmail.com</div> </div> <div> <br/> Date: 05/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div> |
| 7th Feb, 2025 | BSE India | Un-Audited Financial Results for the Quarter and Nine months ended on 31st December 2024 along with Auditor''s Limited Review Report. |
| 7th Feb, 2025 | BSE India | Outcome of the Board Meeting held on 07th February 2025 for approval of Un-audited Financial Results for the Quarter and Nine months ended on 31st December 2024. |
| 31st Jan, 2025 | BSE India | Zenlabs Ethica Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 ,inter alia, to consider and approve The Meeting of the Board of Directors of the Company is scheduled on February 7, 2025 Inter alia, to consider and approve Unaudited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2024 and any other matter with the permission of the Chairman. |
| 8th Jan, 2025 | BSE India | Pursuant to Regulation 74(5) of SEBI (Depositories and Participant) Regulation 2018, we are enclosing herewith the compliance certificate received from M/s Bigshare Services Private Limited, the Registrar and Share Transfer Agent (RTA) of the Company for the Quarter ended December 31, 2024. |
| 12th Nov, 2024 | BSE India | Declaration regarding the non-applicability of Regulation 23(9) of SEBI LODR, Regulations 2015 in respect of disclosure of Related Party transactions for the half year ended on 30th September, 2024. |
| 12th Nov, 2024 | BSE India | Un- audited Financial Results for the Quarter and Half year ended on 30th September, 2024 along with Auditor''s Limited Review Report. |
| 12th Nov, 2024 | BSE India | Outcome of the Board Meeting held on 12th November, 2024 for approval of Un-audited financial results for the Quarter and Half year ended on 30th September, 2024. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 1st Feb, 2025 | 7th Feb, 2025 |
| Quarterly Results | -- | 8th Nov, 2024 | 12th Nov, 2024 |
| Quarterly Results | -- | 1st Aug, 2024 | 7th Aug, 2024 |
| Audited Results | -- | 14th May, 2024 | 20th May, 2024 |
| Quarterly Results | -- | 24th Jan, 2024 | 29th Jan, 2024 |
| Quarterly Results | -- | 27th Oct, 2023 | 6th Nov, 2023 |
| Quarterly Results | -- | 20th Jul, 2023 | 28th Jul, 2023 |
| Audited Results | -- | 18th May, 2023 | 24th May, 2023 |
| Quarterly Results | -- | 3rd Feb, 2023 | 9th Feb, 2023 |
| Quarterly Results | -- | 12th Oct, 2022 | 18th Oct, 2022 |
Share Holding Pattern
Loading...
Loading...
| Owner Name | Mar, 2025 | Sept, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
|---|---|---|---|---|---|
| Promoter Group | 52.96% | 52.96% | 59.12% | 59.12% | 67.61% |
| Foreign Institutions + | 0% | 0% | 0% | 0% | 0% |
| Domestic Institutions + | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 47.04% | 47.04% | 40.88% | 40.88% | 32.39% |
| Others | 0% | 0% | 0% | 0% | 0% |
About Zenlabs Ethica
Zenlabs Ethica is a Public Limited Listed company incorporated on 20/07/1993 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L74900CH1993PLC033112 and registration number is 033112. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 58.56 Cr. and Equity Capital is Rs. 6.51 Cr. for the Year ended 31/03/2024.
Parent Organisation
Not Applicable
Founded
1993
Managing Director
Mr. Sanjeev Kumar
NSE Symbol
--
Zenlabs Ethica Management
| Name | Designation |
|---|---|
| Mr. Sanjeev Kumar | Managing Director & CEO |
| Mr. Sanjay Dhir | Whole Time Executive Director |
| Ms. Himjyoti | Non Executive Director |
| Mr. Anurag Malhotra | Independent Director |
| Mr. Kuldeep Singh | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,39,630.15 | ₹1,832.30  ₹1,805.50(1.48%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,61,590.72 | ₹6,087.00  ₹6,108.00(-0.34%) | ₹3,725.550 - ₹6,448.750 |
| Cipla | ₹1,25,192.34 | ₹1,550.10 ₹1,541.50(0.56%) | ₹1,310.050 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,12,431.58 | ₹3,322.00 ₹3,322.70(-0.02%) | ₹2,513.050 - ₹3,589.950 |
| Mankind Pharma | ₹1,01,712.98 | ₹2,465.30 ₹2,556.90(-3.58%) | ₹1,910.100 - ₹3,050.000 |
FAQs on Zenlabs Ethica
What is the share price of Zenlabs Ethica?
The share price of Zenlabs Ethica on 30th Apr, 2025 is ₹ 31.39.
What is 52W high and 52W low share price of Zenlabs Ethica?
The highest and lowest 52W share prices of Zenlabs Ethica are ₹ 52.400 and ₹ 27.330
What is the market cap of Zenlabs Ethica?
The market capitalization of Zenlabs Ethica as of 30th Apr, 2025 is ₹ 20.43 Crores
What is the P/E ratio of Zenlabs Ethica?
The current P/E ratio of Zenlabs Ethica as of 30th Apr, 2025 is 46.55
What is the PB ratio of Zenlabs Ethica?
The PB ratio of Zenlabs Ethica as of 30th Apr, 2025 is 2.02
Top Gainers
₹78.00
₹65.00 (0.20%)
₹121.03
₹100.86 (0.20%)
₹13.15
₹11.00 (0.20%)
₹1.88
₹1.57 (0.20%)
Top Losers
₹107.95
₹123.00 (-0.12%)
₹0.50
₹0.56 (-0.11%)
₹24.55
₹28.11 (-0.13%)
₹3.34
₹3.80 (-0.12%)
Market Indices
Sensex
₹80,242.24
₹80,288.38 (0.00%)
Source : Dion Global Solutions Limited